1018-00009 · Client 1018 · Strategy

penalty-protection-analysis-memo.docx DOCUMENT M&A / Corporate

162 / 176 ← → ✕

PRIVILEGED AND CONFIDENTIAL ATTORNEY WORK PRODUCT

This memorandum constitutes attorney work product prepared in anticipation of litigation and is protected by the attorney-client privilege and the work product doctrine. This document and its contents are not to be disclosed to any person or entity outside of Calderwood & Harkness LLP, Penterra Pharmaceuticals Corp.'s in-house legal and tax departments, and professionals retained under Kovel arrangements, without the express written authorization of the undersigned or the Responsible Partner.

CALDERWOOD & HARKNESS LLP

Tax Department — Research Memorandum

FROM: Garrett Simmons, Lead Associate, Tax Department, Calderwood & Harkness LLP

TO: Leonard Cross, Responsible Partner; Sylvia Hartwell, Billing Partner

DATE: September 2, 2022

RE: IRC § 6662(e) Penalty Protection and Reasonable Cause Defense — Penterra Pharmaceuticals Corp. IRS Transfer Pricing Examination (TY 2017–2020)

MATTER NUMBER: 1018-00009

CLIENT: Penterra Pharmaceuticals Corp. (EIN: 22-3741856)

EXAM TEAM ID: LB&I-NE-TP-2022-00641

PRIVILEGE DESIGNATION: Attorney-Client Privileged and Attorney Work Product — Prepared in Anticipation of Litigation

Right-click to update Table of Contents

I. Executive Summary

The purpose of this memorandum is to analyze Penterra Pharmaceuticals Corp.'s ("PPC" or the "Company") exposure to transfer pricing penalties under Internal Revenue Code ("IRC") § 6662(e) and to assess the strength of available defenses, with particular focus on the reasonable cause and contemporaneous documentation defenses set forth in IRC § 6662(e)(3)(B) and the implementing regulations at Treas. Reg. § 1.6662-6.

The Internal Revenue Service ("IRS"), Large Business & International Division ("LB&I"), opened an examination of PPC's federal income tax returns for Tax Years ("TY") 2017 through 2020 on May 16, 2022, as communicated by Letter 2205-A. The examination is assigned to the LB&I Northeast Transfer Pricing Practice under Exam Team ID LB&I-NE-TP-2022-00641. Based on initial Information Document Requests ("IDRs") and informal communications with the exam team, the IRS's examination challenges the transfer pricing methodology used in connection with PPC's Irish intellectual property ("IP")-holding structure involving Penterra Biopharma International DAC ("PBI"), a designated activity company organized under Irish law and PPC's principal overseas IP-holding and licensing entity.

Based on our assessment of the examination's trajectory, we anticipate that the IRS will focus on three primary areas of adjustment:

(a) CSA Cost-Sharing Ratios. The IRS is expected to challenge the cost-sharing percentages applied under the qualified cost-sharing arrangement ("CSA") between PPC and PBI, under which PBI's share of annual qualified research and development ("R&D") costs ranged from $487.3 million to $598.4 million during TY 2017–2020. The IRS may assert that PBI's cost-sharing percentages (38.2% to 42.7% across the examination years) understate PBI's reasonably anticipated benefits from covered intangibles and therefore result in an underpayment of PBI's cost-sharing obligations.

(b) Legacy IP Royalty Rates. The IRS is expected to challenge the royalty rate of 4.5% of non-Americas net sales applied by PPC to licenses of legacy IP (i.e., IP developed prior to the July 1, 2012 inception of the CSA) to PBI. The IRS may contend that an arm's-length royalty rate significantly exceeds 4.5%, potentially in the range of 9% to 12% or higher.

(c) Platform Contribution Transaction ("PCT") Valuation. The IRS is expected to scrutinize the $312 million PCT payment made by PBI to PPC on July 1, 2012, in connection with the buy-in of pre-existing intangible property to the CSA. Although the PCT was executed outside the examination years, the IRS may argue that the PCT undervalued the contributed intangibles, with downstream implications for the cost-sharing and royalty arrangements during TY 2017–2020.

If the IRS proposes substantial adjustments in any or all of these areas — which, at this early stage of the examination, we anticipate could be significant given the magnitude of intercompany flows (aggregate intercompany transactions during TY 2017–2020 exceeded $3.5 billion) — penalty exposure under IRC § 6662(e) could reach 20% of the underpayment attributable to the IRC § 482 allocation. In cases where the IRS asserts a gross valuation misstatement, the penalty rate increases to 40% under IRC § 6662(h). Preliminary estimates of penalty exposure, assuming a net proposed adjustment in the range of $300 million to $400 million across all four years, range from approximately $12.6 million to $16.8 million at the 20% penalty rate, and from approximately $25.2 million to $33.6 million at the 40% rate. These estimates are detailed in Section VIII and Appendix C below.

Conclusion. Based on our analysis, PPC has a strong defense against the imposition of IRC § 6662(e) penalties. This conclusion rests on two principal grounds:

First, PPC possesses contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP ("Crestfield"), under the direction of Martin Ogilvy (Engagement Partner) and Susan Lam (Transfer Pricing Partner), for all four examination years. The documentation was prepared annually, was in existence at the time PPC's federal income tax returns were filed for each respective year, and was timely produced to the IRS within 30 days of the IRS's request. The documentation substantially satisfies the requirements of Treas. Reg. § 1.6662-6(d), thereby establishing the statutory safe harbor under IRC § 6662(e)(3)(B)(ii).

Second, PPC has a robust reasonable cause and good faith defense grounded in the Company's reliance on qualified professional advisors — including Crestfield for original documentation, and now Calderwood & Harkness LLP ("C&H") and Whitmore Valuation Group ("Whitmore") for examination defense and independent economic analyses — and the substantive quality of PPC's documentation and transfer pricing methodologies. PPC's transfer pricing positions are supported by credible economic analysis, reasonable methodological choices, and the genuine economic substance of PBI, all of which demonstrate that PPC acted in good faith in complying with the arm's-length standard.

We recommend that PPC take several near-term steps to strengthen its penalty defense posture, as detailed in Section IX below. This memorandum should be updated when the IRS issues its Notice of Proposed Adjustment ("NOPA") and the specific penalty positions become known.

II. Statutory and Regulatory Framework

This Section provides a comprehensive overview of the statutory and regulatory framework governing the imposition and defense of transfer pricing penalties. An understanding of this framework is essential to assessing PPC's penalty exposure and the strength of its available defenses.

A. IRC § 6662(a) and (b)(3) — Accuracy-Related Penalty Generally

IRC § 6662(a) imposes a penalty equal to 20% of the portion of any underpayment of tax that is attributable to one or more of the categories of misconduct enumerated in § 6662(b). Among the grounds for the accuracy-related penalty, § 6662(b)(3) includes any "substantial valuation misstatement under chapter 1." The penalty thus applies to the portion of the underpayment — not the entire underpayment — that is attributable to the identified misstatement. This apportionment is significant in transfer pricing cases where the IRS may propose adjustments to multiple intercompany transactions, only some of which may implicate the penalty thresholds.

It is important to note that the accuracy-related penalty provisions of § 6662 are coordinated to prevent stacking. Under § 6662(c), the maximum penalty rate under § 6662 with respect to any portion of an underpayment is 20% (or 40% in the case of a gross valuation misstatement under § 6662(h)), regardless of the number of penalty grounds that may apply to the same portion. Thus, if the IRS were to assert both a substantial valuation misstatement and negligence with respect to the same portion of an underpayment, the penalty would not exceed 20% (or 40%, as applicable). This coordination rule limits the aggregate penalty exposure but does not reduce the importance of defending against any individual penalty ground, as the IRS need prevail on only one ground to sustain the penalty.

B. IRC § 6662(e) — Substantial Valuation Misstatement Defined (Transfer Pricing Context)

IRC § 6662(e) defines the circumstances under which a "substantial valuation misstatement" exists in the transfer pricing context. The provision establishes two alternative tests, either of which, if met, triggers the substantial valuation misstatement penalty:

(i) The Per-Transaction (200%/50%) Test. Under § 6662(e)(1)(B)(i), a substantial valuation misstatement exists if the price for any property or services (or for the use of property) claimed on any return is 200% or more of the amount determined under IRC § 482 to be the correct price, or is 50% or less of such amount. This test is applied on a transaction-by-transaction (or, more precisely, item-by-item) basis, comparing the taxpayer's reported price to the arm's-length price as determined by the IRS.

(ii) The Net § 482 Adjustment Test. Under § 6662(e)(1)(B)(ii), a substantial valuation misstatement exists if the net IRC § 482 transfer price adjustment for the taxable year exceeds the lesser of $5 million or 10% of the taxpayer's gross receipts for the year.

Application to PPC. Both tests are potentially implicated by the anticipated IRS adjustments:

With respect to the net § 482 adjustment test, PPC reported consolidated gross revenues of approximately $6.82 billion for FY 2020. The 10% threshold would therefore be approximately $682 million, a level that would not be exceeded unless the IRS proposes an exceptionally large aggregate adjustment. However, the alternative $5 million threshold could be easily triggered. Given the magnitude of PPC's intercompany flows — with annual CSA cost-sharing payments by PBI ranging from approximately $186 million (38.2% of $487.3 million) to approximately $255 million (42.7% of $598.4 million), and annual legacy royalty payments ranging from approximately $28 million to $37 million during the examination period — even a modest percentage reallocation by the IRS could produce a net adjustment exceeding $5 million in any given year. If the IRS proposes adjustments approaching or exceeding $5 million in any year (which we believe is highly likely), the substantial valuation misstatement threshold will be met, and the penalty inquiry will proceed to the question of available defenses.

With respect to the per-transaction (200%/50%) test, the IRS has signaled interest in PPC's royalty rate of 4.5% on legacy IP licenses. If the IRS were to assert that the arm's-length royalty rate is 9.0% or higher, PPC's claimed rate of 4.5% would be 50% or less of the asserted correct rate, triggering the per-transaction test. More specifically, if the IRS asserts a rate of 11.0%, PPC's rate of 4.5% represents approximately 40.9% of the asserted correct rate, which is below the 50% threshold. This analysis underscores the importance of the IRS's ultimate position on the royalty rate: if the asserted correct rate is less than 9.0% (i.e., 4.5% × 2), the per-transaction test would not be triggered on the royalty component specifically. However, the net adjustment test would still apply to all transfer pricing adjustments in the aggregate.

C. IRC § 6662(h) — Gross Valuation Misstatement

IRC § 6662(h) provides for an enhanced penalty rate of 40% — double the standard rate — where the valuation misstatement rises to the level of a "gross valuation misstatement." In the transfer pricing context, § 6662(h)(2)(C) defines a gross valuation misstatement as arising where:

(i) the claimed price is 400% or more (or 25% or less) of the correct IRC § 482 price; or

(ii) the net IRC § 482 adjustment for the taxable year exceeds the lesser of $20 million or 20% of the taxpayer's gross receipts.

Application to PPC. The per-transaction gross valuation misstatement test (400%/25%) is unlikely to be triggered with respect to any of PPC's intercompany transactions, as the IRS would need to assert that the correct royalty rate is 18.0% or higher (such that PPC's 4.5% is 25% or less of the correct rate), or that the correct rate is 1.125% or lower (such that PPC's 4.5% is 400% or more of the correct rate). Neither scenario appears plausible.

The net adjustment gross valuation misstatement test is more concerning. The $20 million threshold may be triggered if the IRS's total proposed adjustment across all intercompany transactions is sufficiently large. Given the magnitude of PPC's intercompany flows, a total adjustment in the range of $300 million to $400 million (as we anticipate) would produce a tax underpayment at the 21% rate of $63 million to $84 million for TY 2018–2020, and at the 35% rate of potentially even larger amounts for TY 2017, well in excess of the $20 million net adjustment threshold. The 20% of gross receipts threshold (approximately $1.364 billion for FY 2020) is unlikely to be met.

Critically, the reasonable cause/good faith defense and the contemporaneous documentation defense remain available to defeat even the gross valuation misstatement penalty. However, an important distinction applies: under § 6662(h)(3), if the 40% rate applies, the contemporaneous documentation defense alone is insufficient — the taxpayer must independently establish reasonable cause and good faith to avoid the enhanced penalty. This distinction highlights the importance of building a robust reasonable cause defense that is not exclusively dependent on the existence of contemporaneous documentation.

D. IRC § 6662(e)(3)(B) — Exclusion for Taxpayers with Contemporaneous Documentation

IRC § 6662(e)(3)(B) establishes the primary defense mechanism in transfer pricing penalty cases. The provision creates a two-tier protection against the imposition of penalties:

First Tier — General Reasonable Cause. Under § 6662(e)(3)(B)(i), the § 6662(e) penalty shall not apply to any portion of an underpayment if the taxpayer establishes that there was reasonable cause for such portion and that the taxpayer acted in good faith with respect to such portion. This is a general reasonable cause defense, applicable regardless of whether the taxpayer has contemporaneous documentation.

Second Tier — Contemporaneous Documentation Safe Harbor. Under § 6662(e)(3)(B)(ii), a taxpayer that meets the documentation requirements prescribed by the Secretary (i.e., the requirements set forth in Treas. Reg. § 1.6662-6(d)) shall be treated as having established reasonable cause under subparagraph (B)(i) if:

(a) the documentation was in existence at the time the return was filed (i.e., the documentation was "contemporaneous"), and

(b) the taxpayer provides such documentation to the Secretary within 30 days of a request therefor (or such longer period as may be agreed upon between the taxpayer and the Secretary).

The contemporaneous documentation safe harbor effectively creates a rebuttable presumption of reasonable cause: if the taxpayer's documentation meets the regulatory requirements, was in existence at the time of filing, and was timely produced, the taxpayer is treated as having satisfied the reasonable cause standard. This is a powerful defense, as it shifts the focus from the ultimate correctness of the taxpayer's pricing to whether the taxpayer made a genuine, documented effort to comply with the arm's-length standard.

However, the safe harbor is not absolute. The IRS may overcome the presumption of reasonable cause if it demonstrates that the documentation, although formally compliant, is substantively deficient — for example, if the comparables analysis is unreliable, the method selection is unreasonable, or the documentation fails to reflect the actual facts and circumstances of the controlled transactions. This is why the quality and substance of PPC's documentation, not merely its existence, is critical to the penalty defense.

E. Treas. Reg. § 1.6662-6 — Detailed Penalty Regulations for Transfer Pricing

The Treasury Regulations at § 1.6662-6 provide detailed guidance on the application of the transfer pricing penalty provisions and the requirements for contemporaneous documentation.

Documentation Requirements — Treas. Reg. § 1.6662-6(d)(2). The regulations prescribe two categories of documents that a taxpayer must maintain to satisfy the contemporaneous documentation requirements:

Principal Documents. Under Treas. Reg. § 1.6662-6(d)(2)(iii)(B), the principal documents must include:

(i) An overview of the taxpayer's business, including an analysis of the economic and legal factors that affect the pricing of its property or services;

(ii) A description of the taxpayer's organizational structure (including an organization chart) covering all related parties engaged in transactions potentially relevant under IRC § 482;

(iii) Any documentation explicitly required by the regulations under IRC § 482;

(iv) A description of the method selected and an explanation of why that method was selected, including an evaluation of whether the regulatory conditions for the application of that method are met (the "best method" analysis);

(v) A description of the alternative methods that were considered and an explanation of why they were not selected;

(vi) A description of the controlled transactions (including the terms of sale) and any internal data used to analyze those transactions;

(vii) A description of the comparables that were used, how comparability was evaluated, and what adjustments (if any) were made to the comparables;

(viii) An explanation of the economic analysis and projections relied upon in developing the method;

(ix) A description or summary of any relevant data that the taxpayer obtains after the end of the tax year and before filing a tax return, which would help determine if a taxpayer selected and applied a specified method in a reasonable manner; and

(x) A general index of the principal and background documents and a description of the recordkeeping system used for cataloging and accessing those documents.

Background Documents. Under Treas. Reg. § 1.6662-6(d)(2)(iii)(C), background documents include all documents, notes, work papers, records, or other materials that support the assumptions, conclusions, and positions contained in the principal documents. These documents need not be in existence at the time the return is filed but must be maintained and produced upon request.

Contemporaneousness Requirement — Treas. Reg. § 1.6662-6(d)(2)(ii). The principal documents must be in existence when the return is filed. For PPC, which has a December 31 fiscal year-end and files on extension, this means the documentation must be completed and finalized on or before the extended filing deadline (typically October 15 of the following year for corporate returns, or, for years in which further extensions apply, the date the return is actually filed, whichever is earlier). Documentation created after the return is filed is not "contemporaneous" and does not qualify for the safe harbor, although it may still be relevant to the general reasonable cause defense.

Year-Specific Requirements — Treas. Reg. § 1.6662-6(d)(2)(iii)(A). The regulations require that documentation cover each tax year individually. A taxpayer cannot rely on a single multi-year study without year-specific updates to the economic analysis, comparable data, and financial information. While structural elements of the documentation (e.g., business overview, organizational description) need not be entirely rewritten each year, the economic analysis, comparables data, and supporting calculations must be updated annually to reflect the facts and circumstances of the specific tax year. This requirement is particularly important for PPC, as any failure to update the documentation on a year-by-year basis could undermine the contemporaneous documentation defense.

Timely Production Requirement — Treas. Reg. § 1.6662-6(d)(2)(ii). The taxpayer must provide the documentation to the IRS within 30 days of a request, or such later time as may be agreed upon between the taxpayer and the IRS. Failure to produce documentation within the required time frame is treated as a failure to maintain contemporaneous documentation, regardless of whether the documentation actually existed at the time of filing. This underscores the importance of prompt compliance with IDR requests for transfer pricing documentation.

III. Analysis of PPC's Contemporaneous Transfer Pricing Documentation

A. Documentation Prepared by Crestfield & Associates LLP

For each of TY 2017, 2018, 2019, and 2020, Crestfield & Associates LLP prepared contemporaneous transfer pricing documentation under IRC § 6662(e) penalty-protection standards. The documentation engagement was led by Martin Ogilvy (Engagement Partner) and Susan Lam (Transfer Pricing Partner), both of whom are recognized practitioners in the pharmaceutical and life sciences transfer pricing space. Crestfield has served as PPC's transfer pricing documentation provider since at least 2012, and was also responsible for the original PCT valuation analysis and the initial documentation of the CSA at its inception.

The documentation was prepared annually and, based on our review to date, appears to have been in existence prior to the filing of PPC's Forms 1120 for each respective tax year. PPC has a fiscal year-end of December 31 and has consistently filed its federal income tax returns on extension. The extended filing deadlines for the relevant years were as follows: October 15, 2018 (TY 2017); October 15, 2019 (TY 2018); October 15, 2020 (TY 2019); and October 15, 2021 (TY 2020). The documentation packages include date stamps and engagement letter references that are consistent with completion prior to these deadlines, although this point should be confirmed with Crestfield, as discussed in Section IX.A below.

The Crestfield documentation covers both of the principal intercompany transactions at issue:

(a) The qualified cost-sharing arrangement between PPC and PBI, analyzed under Treas. Reg. § 1.482-7, including the determination of PBI's cost-sharing percentages and the allocation of qualified R&D costs; and

(b) The legacy IP royalty arrangement under which PBI pays PPC a royalty of 4.5% of non-Americas net sales for the license of pre-CSA intangible property, analyzed under Treas. Reg. § 1.482-4.

Additionally, the documentation addresses the contract manufacturing arrangement between PBI and Penterra Manufacturing Ireland Ltd. ("PMI"), under which PMI provides contract manufacturing services to PBI at a cost-plus 8% markup, analyzed under the comparable profits method ("CPM") / transactional net margin method ("TNMM").

B. Assessment of Documentation Completeness Against Regulatory Checklist

We have conducted a preliminary review of the Crestfield documentation for all four tax years against the regulatory checklist prescribed by Treas. Reg. § 1.6662-6(d)(2)(iii)(B). Our assessment is as follows:

Business Overview. The Crestfield documentation includes a comprehensive description of PPC's business operations as a specialty pharmaceutical and biotechnology company operating in oncology, immunology, and rare-disease therapeutics. The overview addresses PPC's position in the global pharmaceutical market, its principal product lines, key therapeutic areas, and competitive landscape. The documentation reflects PPC's FY 2020 consolidated revenue of approximately $6.82 billion and its workforce of approximately 14,500 employees globally. The business overview appears to have been updated annually to reflect material changes in PPC's product portfolio, regulatory approvals, clinical pipeline, and financial performance.

Organizational Structure. The documentation describes PPC's relevant corporate structure, including the key entities in the intercompany transaction chain:

• Penterra Pharmaceuticals Corp. (U.S. parent, publicly traded on NYSE: PPHR)

• Penterra Holdings Luxembourg S.à r.l. ("PHL") — a Luxembourg société à responsabilité limitée that is disregarded as separate from PPC for U.S. federal income tax purposes

• Penterra Biopharma International DAC ("PBI") — an Irish designated activity company that serves as the principal IP-holding and licensing entity outside the Americas

• Penterra Manufacturing Ireland Ltd. ("PMI") — an Irish limited company that provides contract manufacturing services to PBI

The organizational charts included in the documentation depict the ownership chain (PPC → PHL → PBI → PMI) and identify the relevant intercompany agreements governing transactions between these entities.

Controlled Transactions Documented. The documentation addresses the following controlled transactions in detail:

CSA Cost-Sharing. PBI's cost-sharing percentages were determined based on reasonably anticipated benefit ("RAB") projections, with PBI's share increasing from 38.2% in TY 2017 to 42.7% in TY 2020, reflecting PBI's growing share of projected revenues from covered intangibles in non-Americas markets. The annual qualified R&D costs to which these percentages were applied were $487.3 million (TY 2017), $523.8 million (TY 2018), $561.2 million (TY 2019), and $598.4 million (TY 2020). The documentation includes the RAB projections, revenue forecasts by geographic segment, and the resulting cost-sharing calculations for each year.

Legacy IP Royalty. The documentation supports the 4.5% royalty rate applied to PBI's non-Americas net sales for the license of pre-CSA intangible property. Non-Americas net sales subject to the royalty declined from $814.6 million in TY 2017 to $624.1 million in TY 2020, reflecting the natural erosion of legacy product sales and the growing contribution of post-CSA intangibles to PBI's revenue base. The documentation includes the CUT (comparable uncontrolled transaction) analysis supporting the 4.5% rate.

PMI Contract Manufacturing. The documentation supports the cost-plus 8% markup applied to contract manufacturing services provided by PMI to PBI. This transaction is not currently a primary focus of the IRS examination but is documented as part of the comprehensive transfer pricing analysis.

PCT. The original PCT payment of $312 million, made by PBI to PPC on July 1, 2012, is referenced in the documentation for each year as historical background for the CSA. The original PCT valuation, based on a discounted cash flow ("DCF") analysis, is included in the background documents. The ongoing cost-sharing and royalty methodologies are independently documented for each year and do not depend solely on the PCT valuation.

Method Selection and Best Method Analysis. The documentation applies the following methods:

• CUT Method for the legacy IP royalty rate, based on comparable uncontrolled license agreements in the pharmaceutical and biotechnology sectors;

• CPM/TNMM for evaluating PBI's operating margins from exploitation of licensed and cost-shared intangibles, as well as for the PMI contract manufacturing arrangement; and

• Income Method (DCF) for the PCT valuation, consistent with Treas. Reg. § 1.482-7(g)(4).

For each method, the documentation includes a discussion of why the selected method was chosen as the "best method" under Treas. Reg. § 1.482-1(d), including an assessment of the degree of comparability between the controlled and uncontrolled transactions, the quality of the available data, and the reliability of the assumptions underlying the analysis. The documentation also discusses alternative methods that were considered and the reasons they were not selected, consistent with the regulatory requirement.

Comparables Search and Analysis. The documentation includes comparables searches and economic analyses supporting the arm's-length nature of PPC's intercompany pricing. For the CUT analysis of the royalty rate, the documentation identifies comparable uncontrolled license agreements sourced from publicly available databases and proprietary Crestfield datasets. For the CPM/TNMM analysis, the documentation includes searches for comparable companies using standard financial databases.

However, the depth and currency of the comparable data will need to be assessed against the standards applied by courts in transfer pricing penalty cases. As discussed in Section V below, courts have scrutinized the rigor of comparables searches, the relevance and reliability of selected comparables, and the adequacy of comparability adjustments. We recommend that C&H coordinate with Whitmore Valuation Group to assess whether the Crestfield comparables searches and analyses would withstand IRS and judicial scrutiny, and whether supplemental analysis may be advisable to bolster the reasonableness of PPC's positions.

Economic Analysis. Each year's documentation includes quantitative analysis supporting the arm's-length nature of the intercompany pricing. The analysis includes computation of PBI's operating margins, comparison to arm's-length ranges derived from comparable company data, reconciliation of cost-sharing ratios to RAB projections, and sensitivity analyses testing the impact of key assumptions on the reported results. The economic analysis is supported by detailed work papers and financial data for PPC and PBI.

C. Timeliness of Production

IDR No. 4, issued by the IRS examination team approximately in August 2022, requested the contemporaneous transfer pricing documentation for all four tax years (TY 2017–2020). C&H, on behalf of PPC, responded on August 1, 2022, producing the complete Crestfield-prepared documentation packages for all four years. This production was made well within the 30-day production window prescribed by Treas. Reg. § 1.6662-6(d)(2)(ii).

No timeliness objection is available to the IRS with respect to PPC's production of contemporaneous documentation. The documentation was produced promptly, in an organized format, with an index of principal and background documents. The production was accompanied by a cover letter identifying the documents produced and reserving applicable privilege claims with respect to documents withheld under the attorney-client privilege and work product doctrine, consistent with the privilege protocol established by Leonard Cross in a separate memorandum dated June 10, 2022.

D. Potential Weaknesses in Documentation

Notwithstanding the overall strength of PPC's documentation, our preliminary review has identified several areas that require further investigation and, potentially, remediation:

Year-Specific Updating. We need to verify that each year's documentation was independently updated with year-specific financial data, comparables analysis, and economic analysis, and that the documentation does not consist merely of boilerplate carryforwards from prior years with only cosmetic modifications. The regulations require year-specific documentation, and courts have penalized taxpayers whose documentation was essentially a "cut and paste" of prior-year studies without meaningful updates. Specifically, we should confirm that the RAB projections, revenue forecasts, comparable data sets, and financial metrics used in the economic analysis were independently developed or updated for each tax year.

Completeness of Transaction Coverage. We need to confirm that the documentation addresses all transactions the IRS is examining, including whether the CSA cost-sharing ratio calculations are supported with sufficient detail on the RAB projections — specifically, the methodology for projecting PBI's share of reasonably anticipated benefits from covered intangibles, the revenue forecasting models used, and the treatment of pipeline products at various stages of clinical development. If the documentation fails to address any material aspect of the transactions under examination, this gap could be exploited by the IRS in asserting that the documentation is incomplete and therefore does not satisfy the regulatory requirements.

PCT Valuation Linkage. The original PCT valuation of $312 million was performed in 2012, outside the examination years. The documentation for TY 2017–2020 appropriately references the PCT as historical background, but the critical question is whether the ongoing CSA and royalty methodologies are independently documented each year without excessive reliance on the 2012 PCT analysis. If the IRS challenges the PCT valuation and argues that the downstream cost-sharing and royalty arrangements are infected by the same purported errors, PPC's penalty defense will need to demonstrate that the current-year documentation independently supports the arm's-length nature of the ongoing transactions, regardless of the PCT valuation.

Documentation Preparation Timeline. We should obtain from Crestfield (Susan Lam) a detailed description of the documentation preparation process and timeline for each year, including when the engagement was initiated, when draft and final documentation packages were completed, and how the completion dates relate to PPC's return filing dates. This information will be critical in confirming the contemporaneousness of the documentation and in responding to any IRS challenge on this point.

Recommendation. C&H should schedule a meeting with Susan Lam and the Crestfield team at the earliest opportunity to (i) obtain confirmation of the documentation preparation process and timeline for each year, (ii) identify any gaps in year-specific updating, (iii) assess the robustness of the comparables searches and economic analyses, and (iv) discuss any limitations or caveats noted by Crestfield in their engagement letter or documentation deliverables. The results of this meeting should be documented in a follow-up memorandum to the file.

IV. Reasonable Cause and Good Faith Defense — General Standards

Even if the IRS were to contend that PPC's contemporaneous documentation does not fully satisfy the regulatory checklist, PPC retains the general reasonable cause and good faith defense under IRC § 6664(c). This defense is available independently of the contemporaneous documentation safe harbor and may provide an additional layer of protection against the imposition of penalties.

A. Statutory Framework — IRC § 6664(c)

IRC § 6664(c)(1) provides that no penalty shall be imposed under § 6662 with respect to any portion of an underpayment if it is shown that there was reasonable cause for such portion and that the taxpayer acted in good faith with respect to such portion. The statute contemplates a two-part inquiry: (1) whether the taxpayer had "reasonable cause" for the position giving rise to the underpayment, and (2) whether the taxpayer "acted in good faith" in reporting the position on the return.

The burden of proof rests on the taxpayer. PPC must affirmatively demonstrate, by a preponderance of the evidence, that its transfer pricing positions were adopted for reasonable cause and in good faith. This determination is made on a case-by-case basis, taking into account all pertinent facts and circumstances. There is no mechanical test for reasonable cause; rather, the inquiry is inherently fact-intensive and turns on the totality of the circumstances surrounding the taxpayer's reporting position.

B. Treas. Reg. § 1.6664-4 — Reasonable Cause and Good Faith

The Treasury Regulations at § 1.6664-4 provide detailed guidance on the factors relevant to the reasonable cause and good faith determination. The regulations identify several factors that are generally accorded significant weight:

(i) Efforts to Assess Proper Tax Liability. The regulations look to the nature of the taxpayer's efforts to assess its proper tax liability. A taxpayer that takes affirmative steps to determine the correct tax treatment of a transaction — such as engaging qualified professionals, conducting economic analyses, and preparing detailed documentation — is more likely to establish reasonable cause than a taxpayer that takes a reporting position without any supporting analysis.

(ii) Experience, Knowledge, and Education. The taxpayer's own expertise and sophistication are relevant factors. However, the regulations do not penalize sophistication; rather, a sophisticated taxpayer is expected to recognize the complexity of its transactions and to take correspondingly greater care in determining the correct treatment. The regulations acknowledge that even sophisticated taxpayers may reasonably rely on the judgment of qualified professionals in areas of specialized expertise, such as transfer pricing economics.

(iii) Reliance on Professional Advice. A taxpayer's reliance on professional advice is among the most important factors in the reasonable cause analysis. Reliance on professional advice constitutes reasonable cause if three conditions are met:

(a) The adviser was a competent professional who had sufficient expertise to justify reliance — in the transfer pricing context, this typically means an economist or transfer pricing specialist with relevant industry experience;

(b) The taxpayer provided necessary and accurate information to the adviser — i.e., the taxpayer did not withhold material facts or provide misleading data; and

(c) The taxpayer actually relied in good faith on the adviser's judgment — i.e., the reliance was genuine and not merely a post hoc rationalization.

The sophistication of the taxpayer is a relevant factor in assessing the reasonableness of reliance on professional advice. However, even sophisticated taxpayers — including large, publicly traded companies like PPC — can establish reasonable cause through reliance on qualified advisors, particularly in the highly specialized and technical area of transfer pricing economics. The key question is whether the taxpayer's reliance was genuine and reasonable under the circumstances, not whether the taxpayer could theoretically have reached its own conclusion without professional assistance.

C. Application to Transfer Pricing Specifically — Treas. Reg. § 1.6662-6(d)

Under the transfer pricing penalty regulations at Treas. Reg. § 1.6662-6(d), the existence of qualifying contemporaneous documentation creates a rebuttable presumption of reasonable cause. This presumption is the foundation of the contemporaneous documentation safe harbor discussed in Section II.D above.

Importantly, even if the documentation does not fully meet the regulatory checklist — for example, if there are arguable gaps in the comparables analysis, or if certain elements of the best method discussion are less detailed than optimal — a taxpayer may still establish reasonable cause and good faith through other evidence. The regulations contemplate that the quality and detail of the documentation is a factor in the reasonable cause analysis, not a bright-line test. A taxpayer whose documentation substantially (but not perfectly) satisfies the regulatory requirements, and who can demonstrate reliance on qualified professionals and a genuine effort to comply with the arm's-length standard, may nonetheless avoid penalties.

Courts have consistently emphasized that the reasonable cause inquiry in transfer pricing cases focuses on whether the taxpayer made a genuine, good-faith effort to comply with the arm's-length standard — not on whether the taxpayer's position ultimately prevails on the merits. The fact that the IRS disagrees with the taxpayer's transfer pricing methodology or reaches a different arm's-length result does not, standing alone, establish that the taxpayer lacked reasonable cause. To the contrary, the existence of legitimate methodological disputes — which are common in the transfer pricing area given the inherent subjectivity of arm's-length pricing determinations — tends to support, rather than undermine, the taxpayer's reasonable cause defense.

V. Case Law on Transfer Pricing Penalties and Reasonable Cause

The case law on transfer pricing penalties under IRC § 6662(e) provides important guidance on the standards courts apply in evaluating the contemporaneous documentation defense and the reasonable cause defense. While each case turns on its own facts, several principles emerge from the decided cases that are instructive for PPC's penalty defense.

A. Cases Upholding Penalty Protection

A number of cases have found taxpayers entitled to penalty protection based on adequate contemporaneous documentation and/or reasonable cause. These cases illustrate the types of taxpayer conduct that courts view favorably in the penalty context.

Reliance on Qualified Economists and Robust Benchmarking Studies. Courts have consistently held that a taxpayer's engagement of qualified economists to prepare transfer pricing documentation and benchmarking studies weighs strongly in favor of reasonable cause. Where the taxpayer retained professionals with recognized expertise in transfer pricing economics, provided them with accurate and complete information, and relied on their professional judgment in setting intercompany prices, courts have found that the taxpayer acted in good faith. This principle is directly analogous to PPC's engagement of Crestfield & Associates for original documentation and Whitmore Valuation Group for independent economic analyses in connection with the examination.

Good-Faith Reliance on Professional Advisors. Courts have recognized that reliance on the advice of qualified tax professionals — including transfer pricing economists, tax attorneys, and valuation specialists — is a strong indicator of reasonable cause. The reliance need not be blindly mechanical; rather, the taxpayer must demonstrate that it provided its advisors with relevant information, that the advisors applied recognized methodologies to the facts, and that the taxpayer adopted the resulting pricing in good faith. In PPC's case, the engagement of Crestfield for transfer pricing documentation, the retention of C&H for examination defense, and the engagement of Whitmore Valuation Group under a Kovel arrangement all demonstrate a pattern of professional reliance that courts have found persuasive.

Defensible Range Supported by Economic Analysis. Courts have also been reluctant to impose penalties where the taxpayer's transfer pricing position, even if not ultimately sustained, falls within a defensible range supported by economic analysis. A taxpayer whose pricing is within the interquartile range (or even reasonably close to it) of a reliable comparables study is generally not viewed as having engaged in conduct warranting penalties. The fact that the IRS may identify a different arm's-length result, or that the court may adopt a different point within the arm's-length range, does not establish that the taxpayer's position was unreasonable. This principle is particularly relevant to PPC's legacy royalty rate of 4.5%, which falls virtually at the median (4.4%) of the interquartile range (3.1%–6.8%) identified by Whitmore Valuation Group's CUT analysis.

B. Cases Where Penalties Were Sustained

Courts have sustained transfer pricing penalties in cases presenting markedly different facts from those present here. An examination of these cases helps identify the types of conduct that courts view as warranting penalties and, by contrast, the distinctions that support PPC's penalty defense.

Absence of Contemporaneous Documentation. The most straightforward basis for sustaining penalties is the complete absence of any contemporaneous documentation. Where taxpayers failed to prepare any transfer pricing documentation — or prepared documentation only after the IRS opened an examination — courts have consistently found the taxpayer ineligible for the contemporaneous documentation safe harbor and have analyzed the general reasonable cause defense with heightened skepticism. PPC's situation is fundamentally distinguishable: Crestfield prepared contemporaneous documentation for all four tax years, and PPC timely produced the documentation within 30 days of the IRS's request.

Formulaic or Boilerplate Documentation. Courts have also imposed penalties where the taxpayer's documentation was merely formulaic or boilerplate — i.e., identical language repeated across multiple years without year-specific analysis, financial data, or updated comparables. Such documentation fails to demonstrate a genuine effort to comply with the arm's-length standard and does not satisfy the year-specific requirement of Treas. Reg. § 1.6662-6(d)(2)(iii)(A). This risk factor underscores the importance of confirming, as recommended in Section III.D above, that PPC's Crestfield documentation was independently updated for each tax year.

Inadequate Comparables Searches. Courts have scrutinized the rigor of taxpayers' comparables searches and have imposed penalties where the search process was demonstrably inadequate — for example, where the taxpayer selected only favorable comparables while ignoring more reliable comparables that would have produced a different result, or where the search was conducted using overly narrow criteria designed to produce a predetermined outcome. For PPC, the quality of the comparables searches conducted by Crestfield will be a focus of the IRS's penalty analysis, and any weaknesses in the search methodology could be exploited by the IRS.

Unreasonable Method Selection. Penalties have been sustained where the taxpayer's selected method lacked a reasonable basis under the best method rule of Treas. Reg. § 1.482-1(d) — for example, where the taxpayer applied a method that was plainly inferior to an available alternative, or where the taxpayer failed to make appropriate comparability adjustments. PPC's method selections (CUT for royalties, CPM/TNMM for operating margins, income method for PCT) are well-established and widely used in pharmaceutical transfer pricing; the risk on this factor is relatively low, provided the documentation adequately explains the rationale for each method selection.

Untimely Production. Courts have treated untimely production of documentation as equivalent to non-production for purposes of the contemporaneous documentation defense. As noted in Section III.C above, PPC's timely production within 30 days of the IRS's request eliminates this risk.

Key Takeaways for PPC. PPC must be prepared to demonstrate that its documentation is not pro forma but reflects genuine economic analysis tailored to each tax year. The documentation should be presentable as a package that demonstrates, on its face, a serious, good-faith effort to determine arm's-length pricing — not merely a compliance exercise designed to check regulatory boxes. To the extent any weaknesses exist in the Crestfield documentation, they should be identified promptly and addressed through supplemental analyses and testimony.

C. Relevance of Altera and Harborview Corporation Line of Cases

Two recent lines of appellate and Tax Court authority are particularly relevant to PPC's penalty analysis, given their involvement of pharmaceutical intangibles and CSA structures.

Altera Corp. v. Commissioner. In Altera Corp. v. Commissioner, 941 F.3d 1200 (9th Cir. 2019), the Ninth Circuit addressed whether Treas. Reg. § 1.482-7(d)(2) — which required participants in qualified cost-sharing arrangements to share stock-based compensation costs — was a valid exercise of the Treasury Department's regulatory authority. The court upheld the regulation, reversing the Tax Court's decision to the contrary. Although the penalty issues in Altera were not the central focus of the appellate decision, the case is relevant to the extent it establishes the validity of the cost-sharing regulations that PPC's CSA is structured to comply with. Importantly, Altera does not establish that a taxpayer's good-faith reliance on a reasonable interpretation of the cost-sharing regulations — even one that is ultimately rejected by the courts — automatically gives rise to penalties. The key question remains whether the taxpayer's position was adopted in good faith based on reasonable professional advice.

Harborview Corporation, Inc. v. Commissioner. The Harborview Corporation litigation, which involved transfer pricing for medical device intangibles licensed to a Puerto Rico manufacturing subsidiary, is closely analogous to PPC's situation. In Harborview Corporation, Inc. v. Commissioner, 900 F.3d 610 (8th Cir. 2018), the Eighth Circuit remanded the case to the Tax Court for reconsideration of the transfer pricing methodology after finding that the Tax Court had erred in its application of the CUT method. On remand, in Harborview Corporation, Inc. v. Commissioner, T.C. Memo. 2022-84, the Tax Court again addressed the appropriate transfer pricing methodology and, relevantly, the penalty issues arising from the IRS's proposed adjustments to royalty payments for pharmaceutical and medical device intangibles.

The penalty implications of Harborview Corporation are significant for PPC: the case illustrates that the IRS's disagreement with a taxpayer's CUT methodology — even where the court ultimately rejects the taxpayer's specific comparable and adopts a different approach — does not automatically warrant penalties. The existence of a legitimate methodological dispute, supported by economic analysis, is not the type of conduct the penalty provisions are designed to address. To the contrary, the penalty provisions target situations where the taxpayer failed to make a good-faith effort to comply with the arm's-length standard — not situations where qualified professionals applied recognized methodologies and reached a defensible (if ultimately incorrect) conclusion.

Neither Altera nor Harborview Corporation established that having a legitimate methodological dispute with the IRS, supported by economic analysis, automatically triggers penalties. Rather, the weight of authority supports the proposition that where the taxpayer's position is supported by a reasonable economic methodology, applied in good faith by qualified professionals, penalties are generally not sustained.

VI. Application to PPC's Specific Positions

This Section applies the statutory, regulatory, and case law framework discussed above to each of PPC's specific transfer pricing positions at issue in the examination.

A. CSA Cost-Sharing Ratios

PPC's cost-sharing ratios, under which PBI bore 38.2% (TY 2017), 39.6% (TY 2018), 41.1% (TY 2019), and 42.7% (TY 2020) of annual qualified R&D costs, are based on reasonably anticipated benefit ("RAB") projections derived from revenue forecasts for Americas versus non-Americas territories. The cost-sharing methodology is grounded in Treas. Reg. § 1.482-7(e), which prescribes the use of RAB shares as the basis for allocating intangible development costs among CSA participants.

The Crestfield documentation details the projection methodology and supporting data used to derive PBI's cost-sharing percentages, including revenue forecasts by product and geographic segment, the treatment of pipeline products at various stages of clinical development, and the expected trajectory of product launches and market penetration in non-Americas territories. PBI's increasing share over the four-year period (from 38.2% to 42.7%) reflects the growing contribution of non-Americas markets to PPC's global revenue mix, driven by PBI's expanding commercial operations and portfolio of marketed products.

If the IRS proposes an increase of 8 to 12 percentage points in PBI's cost-sharing ratios — for example, asserting that PBI's share should have been approximately 46% to 55% — the critical question for penalty purposes is whether PPC's original ratios are so far from the correct ratios as to constitute a substantial valuation misstatement. We believe the penalty defense is strong for several reasons:

First, PPC's cost-sharing methodology is grounded in the regulations and is based on a recognized approach to projecting RAB shares. The use of revenue-based projections, adjusted for geographic market characteristics and product lifecycle factors, is a standard methodology employed by large pharmaceutical companies in structuring and documenting CSAs.

Second, the methodology was documented in detail by qualified professionals (Crestfield & Associates) on a contemporaneous, annual basis, with year-specific financial data and updated revenue projections for each tax year.

Third, the nature of the disagreement between PPC and the IRS is likely to involve subjective assumptions about future revenues, discount rates, and market growth — exactly the type of legitimate methodological dispute that courts have recognized as a basis for penalty protection, not penalty imposition.

The $5 million net adjustment threshold under § 6662(e)(1)(B)(ii) will likely be exceeded on the CSA component alone, as even a modest percentage increase in PBI's cost-sharing ratios, applied to annual qualified R&D costs of $487 million to $598 million, could produce additional U.S. taxable income in excess of $5 million per year. However, exceeding this threshold merely triggers the penalty inquiry — it does not foreclose the reasonable cause defense. As discussed in Section IV above, PPC can establish reasonable cause through contemporaneous documentation and reliance on qualified professional advisors, regardless of the magnitude of the adjustment.

B. Legacy IP Royalty Rate (4.5%)

PPC's legacy IP royalty rate of 4.5% of non-Americas net sales is based on a CUT analysis conducted by Crestfield as part of the contemporaneous documentation for each year, and independently validated by Whitmore Valuation Group in connection with the current examination.

Whitmore's CUT analysis, conducted by Dr. Helena Vasquez and Dr. Rohan Chakrabarti, identified 14 comparable uncontrolled pharmaceutical license agreements involving the out-licensing of oncology, immunology, and specialty pharmaceutical intangibles to unrelated licensees. The agreements were sourced from publicly available databases (including Vireo Health IT, Sundial Health IT, and the SEC EDGAR filing database) and from Whitmore's proprietary transaction database. After applying comparability adjustments for differences in therapeutic area, stage of development, geographic scope, exclusivity provisions, and remaining patent life, the analysis produced an interquartile range of 3.1% to 6.8% with a median of 4.4%.

PPC's royalty rate of 4.5% is virtually at the median of the comparable range (4.4%) and well within the interquartile range (3.1%–6.8%). This positioning provides strong penalty protection:

Under the standards discussed in Section V above, courts have consistently held that a taxpayer whose transfer pricing falls within the interquartile range of a reliable comparables study has demonstrated reasonable cause for its pricing. The fact that the IRS may propose a higher rate does not establish that PPC's rate was unreasonable — it merely reflects a difference of professional judgment in the application of the CUT method.

Even if the IRS were to propose an arm's-length rate of 11.0% — a position that, if sustained, would imply that PPC's 4.5% rate is approximately 40.9% of the correct rate and would trigger the per-item 50% test under § 6662(e)(1)(B)(i) — PPC's penalty defense would remain strong. The per-item test merely triggers the penalty inquiry; it does not override the reasonable cause defense. PPC's reliance on a CUT analysis supported by 14 pharmaceutical comparables, conducted by qualified professionals using recognized databases and methodologies, constitutes strong reasonable cause for the 4.5% rate regardless of whether the IRS proposes a significantly different rate.

Moreover, the 200%/50% test analysis depends on the IRS's ultimate adjustment being sustained, which is the very question in dispute. If the IRS proposes an 11.0% rate but the ultimate arm's-length rate (as determined through settlement or litigation) is less than 9.0%, the per-item test would not be triggered at all. The penalty analysis thus cannot be divorced from the substantive merits of PPC's transfer pricing position, which we believe are defensible.

C. PCT Valuation ($312M)

While the PCT payment of $312 million was made on July 1, 2012, outside the examination years (TY 2017–2020), the IRS may attempt to use the PCT valuation as a basis for adjusting ongoing cost-sharing and royalty arrangements during the examination period. Specifically, the IRS may argue that the PCT undervalued the pre-existing intangible property contributed by PPC to the CSA, and that this undervaluation has cascading effects on the cost-sharing ratios and royalty rates applied in subsequent years.

PPC's PCT valuation is supported by a DCF analysis prepared by Crestfield at the time of the CSA inception in 2012. The analysis applied a weighted average cost of capital ("WACC") of 9.8%, reflecting PPC's blended cost of debt and equity at the time of the transaction, adjusted for the risk characteristics of the intangible property portfolio being contributed. Whitmore Valuation Group has independently reviewed the PCT valuation and, applying a range of discount rates reflecting comparable pharmaceutical company WACCs and asset-specific risk premiums, has concluded that the arm's-length range for the PCT payment is $278 million to $361 million. PPC's actual payment of $312 million falls comfortably within this range.

The IRS is expected to take the position that the appropriate WACC is lower — potentially 7.2%, reflecting a more favorable risk assessment of the contributed intangibles — which would increase the present value of the intangible property and, consequently, the implied arm's-length PCT payment. However, the difference between a 9.8% WACC and a 7.2% WACC represents a legitimate professional disagreement on the appropriate risk-adjusted discount rate for pharmaceutical intangibles, not the type of egregious or unreasonable position that warrants penalties.

The use of a defensible WACC, based on recognized valuation methodologies and supported by comparable company data, constitutes strong reasonable cause for the PCT valuation and for any downstream adjustments flowing from the PCT to the ongoing cost-sharing and royalty arrangements. Moreover, the ongoing CSA cost-sharing ratios and royalty rates are independently documented and supported by separate economic analyses for each tax year, so the penalty defense does not rest solely on the PCT valuation.

D. PBI Economic Substance

The IRS may challenge the economic substance of PBI as part of its broader attack on PPC's transfer pricing structure. While economic substance is more directly relevant to the underlying adjustment (i.e., whether PBI should be respected as a separate entity for transfer pricing purposes) than to the penalty analysis per se, PBI's substance is nonetheless relevant to the penalty defense in two respects.

First, to the extent the IRS argues that PBI is a sham entity without genuine business operations, PPC's documentation of PBI's substance demonstrates that PPC had a good-faith basis for treating PBI as a genuine operating entity with sufficient substance to justify its role as IP owner and CSA participant. PPC can point to the following indicators of PBI's economic substance:

• PBI employed 185 personnel as of the end of 2020, up from 52 employees at the time of the CSA inception in 2012, reflecting significant growth in PBI's operational capabilities over the examination period;

• PBI's board of directors held 42 board meetings in Dublin during TY 2017–2020 (an average of more than 10 meetings per year), at which the board exercised independent judgment on pricing decisions, licensing strategy, regulatory matters, and business development;

• PBI incurred cumulative regulatory expenditures of €47.2 million during TY 2017–2020,

PRIVILEGED AND CONFIDENTIAL ATTORNEY WORK PRODUCT
This memorandum constitutes attorney work product prepared in anticipation of litigation and is protected by the attorney-client privilege and the work product doctrine. This document and its contents are not to be disclosed to any person or entity outside of Calderwood & Harkness LLP, Penterra Pharmaceuticals Corp.'s in-house legal and tax departments, and professionals retained under Kovel arrangements, without the express written authorization of the undersigned or the Responsible Partner.
CALDERWOOD & HARKNESS LLP
Tax Department — Research Memorandum
FROM: Garrett Simmons, Lead Associate, Tax Department, Calderwood & Harkness LLP
TO: Leonard Cross, Responsible Partner; Sylvia Hartwell, Billing Partner
DATE: September 2, 2022
RE: IRC § 6662(e) Penalty Protection and Reasonable Cause Defense — Penterra Pharmaceuticals Corp. IRS Transfer Pricing Examination (TY 2017–2020)
MATTER NUMBER: 1018-00009
CLIENT: Penterra Pharmaceuticals Corp. (EIN: 22-3741856)
EXAM TEAM ID: LB&I-NE-TP-2022-00641
PRIVILEGE DESIGNATION: Attorney-Client Privileged and Attorney Work Product — Prepared in Anticipation of Litigation
Right-click to update Table of Contents
I. Executive Summary
The purpose of this memorandum is to analyze Penterra Pharmaceuticals Corp.'s ("PPC" or the "Company") exposure to transfer pricing penalties under Internal Revenue Code ("IRC") § 6662(e) and to assess the strength of available defenses, with particular focus on the reasonable cause and contemporaneous documentation defenses set forth in IRC § 6662(e)(3)(B) and the implementing regulations at Treas. Reg. § 1.6662-6.
The Internal Revenue Service ("IRS"), Large Business & International Division ("LB&I"), opened an examination of PPC's federal income tax returns for Tax Years ("TY") 2017 through 2020 on May 16, 2022, as communicated by Letter 2205-A. The examination is assigned to the LB&I Northeast Transfer Pricing Practice under Exam Team ID LB&I-NE-TP-2022-00641. Based on initial Information Document Requests ("IDRs") and informal communications with the exam team, the IRS's examination challenges the transfer pricing methodology used in connection with PPC's Irish intellectual property ("IP")-holding structure involving Penterra Biopharma International DAC ("PBI"), a designated activity company organized under Irish law and PPC's principal overseas IP-holding and licensing entity.
Based on our assessment of the examination's trajectory, we anticipate that the IRS will focus on three primary areas of adjustment:
(a) CSA Cost-Sharing Ratios. The IRS is expected to challenge the cost-sharing percentages applied under the qualified cost-sharing arrangement ("CSA") between PPC and PBI, under which PBI's share of annual qualified research and development ("R&D") costs ranged from $487.3 million to $598.4 million during TY 2017–2020. The IRS may assert that PBI's cost-sharing percentages (38.2% to 42.7% across the examination years) understate PBI's reasonably anticipated benefits from covered intangibles and therefore result in an underpayment of PBI's cost-sharing obligations.
(b) Legacy IP Royalty Rates. The IRS is expected to challenge the royalty rate of 4.5% of non-Americas net sales applied by PPC to licenses of legacy IP (i.e., IP developed prior to the July 1, 2012 inception of the CSA) to PBI. The IRS may contend that an arm's-length royalty rate significantly exceeds 4.5%, potentially in the range of 9% to 12% or higher.
(c) Platform Contribution Transaction ("PCT") Valuation. The IRS is expected to scrutinize the $312 million PCT payment made by PBI to PPC on July 1, 2012, in connection with the buy-in of pre-existing intangible property to the CSA. Although the PCT was executed outside the examination years, the IRS may argue that the PCT undervalued the contributed intangibles, with downstream implications for the cost-sharing and royalty arrangements during TY 2017–2020.
If the IRS proposes substantial adjustments in any or all of these areas — which, at this early stage of the examination, we anticipate could be significant given the magnitude of intercompany flows (aggregate intercompany transactions during TY 2017–2020 exceeded $3.5 billion) — penalty exposure under IRC § 6662(e) could reach 20% of the underpayment attributable to the IRC § 482 allocation. In cases where the IRS asserts a gross valuation misstatement, the penalty rate increases to 40% under IRC § 6662(h). Preliminary estimates of penalty exposure, assuming a net proposed adjustment in the range of $300 million to $400 million across all four years, range from approximately $12.6 million to $16.8 million at the 20% penalty rate, and from approximately $25.2 million to $33.6 million at the 40% rate. These estimates are detailed in Section VIII and Appendix C below.
Conclusion. Based on our analysis, PPC has a strong defense against the imposition of IRC § 6662(e) penalties. This conclusion rests on two principal grounds:
First, PPC possesses contemporaneous transfer pricing documentation prepared by Crestfield & Associates LLP ("Crestfield"), under the direction of Martin Ogilvy (Engagement Partner) and Susan Lam (Transfer Pricing Partner), for all four examination years. The documentation was prepared annually, was in existence at the time PPC's federal income tax returns were filed for each respective year, and was timely produced to the IRS within 30 days of the IRS's request. The documentation substantially satisfies the requirements of Treas. Reg. § 1.6662-6(d), thereby establishing the statutory safe harbor under IRC § 6662(e)(3)(B)(ii).
Second, PPC has a robust reasonable cause and good faith defense grounded in the Company's reliance on qualified professional advisors — including Crestfield for original documentation, and now Calderwood & Harkness LLP ("C&H") and Whitmore Valuation Group ("Whitmore") for examination defense and independent economic analyses — and the substantive quality of PPC's documentation and transfer pricing methodologies. PPC's transfer pricing positions are supported by credible economic analysis, reasonable methodological choices, and the genuine economic substance of PBI, all of which demonstrate that PPC acted in good faith in complying with the arm's-length standard.
We recommend that PPC take several near-term steps to strengthen its penalty defense posture, as detailed in Section IX below. This memorandum should be updated when the IRS issues its Notice of Proposed Adjustment ("NOPA") and the specific penalty positions become known.
II. Statutory and Regulatory Framework
This Section provides a comprehensive overview of the statutory and regulatory framework governing the imposition and defense of transfer pricing penalties. An understanding of this framework is essential to assessing PPC's penalty exposure and the strength of its available defenses.
A. IRC § 6662(a) and (b)(3) — Accuracy-Related Penalty Generally
IRC § 6662(a) imposes a penalty equal to 20% of the portion of any underpayment of tax that is attributable to one or more of the categories of misconduct enumerated in § 6662(b). Among the grounds for the accuracy-related penalty, § 6662(b)(3) includes any "substantial valuation misstatement under chapter 1." The penalty thus applies to the portion of the underpayment — not the entire underpayment — that is attributable to the identified misstatement. This apportionment is significant in transfer pricing cases where the IRS may propose adjustments to multiple intercompany transactions, only some of which may implicate the penalty thresholds.
It is important to note that the accuracy-related penalty provisions of § 6662 are coordinated to prevent stacking. Under § 6662(c), the maximum penalty rate under § 6662 with respect to any portion of an underpayment is 20% (or 40% in the case of a gross valuation misstatement under § 6662(h)), regardless of the number of penalty grounds that may apply to the same portion. Thus, if the IRS were to assert both a substantial valuation misstatement and negligence with respect to the same portion of an underpayment, the penalty would not exceed 20% (or 40%, as applicable). This coordination rule limits the aggregate penalty exposure but does not reduce the importance of defending against any individual penalty ground, as the IRS need prevail on only one ground to sustain the penalty.
B. IRC § 6662(e) — Substantial Valuation Misstatement Defined (Transfer Pricing Context)
IRC § 6662(e) defines the circumstances under which a "substantial valuation misstatement" exists in the transfer pricing context. The provision establishes two alternative tests, either of which, if met, triggers the substantial valuation misstatement penalty:
(i) The Per-Transaction (200%/50%) Test. Under § 6662(e)(1)(B)(i), a substantial valuation misstatement exists if the price for any property or services (or for the use of property) claimed on any return is 200% or more of the amount determined under IRC § 482 to be the correct price, or is 50% or less of such amount. This test is applied on a transaction-by-transaction (or, more precisely, item-by-item) basis, comparing the taxpayer's reported price to the arm's-length price as determined by the IRS.
(ii) The Net § 482 Adjustment Test. Under § 6662(e)(1)(B)(ii), a substantial valuation misstatement exists if the net IRC § 482 transfer price adjustment for the taxable year exceeds the lesser of $5 million or 10% of the taxpayer's gross receipts for the year.
Application to PPC. Both tests are potentially implicated by the anticipated IRS adjustments:
With respect to the net § 482 adjustment test, PPC reported consolidated gross revenues of approximately $6.82 billion for FY 2020. The 10% threshold would therefore be approximately $682 million, a level that would not be exceeded unless the IRS proposes an exceptionally large aggregate adjustment. However, the alternative $5 million threshold could be easily triggered. Given the magnitude of PPC's intercompany flows — with annual CSA cost-sharing payments by PBI ranging from approximately $186 million (38.2% of $487.3 million) to approximately $255 million (42.7% of $598.4 million), and annual legacy royalty payments ranging from approximately $28 million to $37 million during the examination period — even a modest percentage reallocation by the IRS could produce a net adjustment exceeding $5 million in any given year. If the IRS proposes adjustments approaching or exceeding $5 million in any year (which we believe is highly likely), the substantial valuation misstatement threshold will be met, and the penalty inquiry will proceed to the question of available defenses.
With respect to the per-transaction (200%/50%) test, the IRS has signaled interest in PPC's royalty rate of 4.5% on legacy IP licenses. If the IRS were to assert that the arm's-length royalty rate is 9.0% or higher, PPC's claimed rate of 4.5% would be 50% or less of the asserted correct rate, triggering the per-transaction test. More specifically, if the IRS asserts a rate of 11.0%, PPC's rate of 4.5% represents approximately 40.9% of the asserted correct rate, which is below the 50% threshold. This analysis underscores the importance of the IRS's ultimate position on the royalty rate: if the asserted correct rate is less than 9.0% (i.e., 4.5% × 2), the per-transaction test would not be triggered on the royalty component specifically. However, the net adjustment test would still apply to all transfer pricing adjustments in the aggregate.
C. IRC § 6662(h) — Gross Valuation Misstatement
IRC § 6662(h) provides for an enhanced penalty rate of 40% — double the standard rate — where the valuation misstatement rises to the level of a "gross valuation misstatement." In the transfer pricing context, § 6662(h)(2)(C) defines a gross valuation misstatement as arising where:
(i) the claimed price is 400% or more (or 25% or less) of the correct IRC § 482 price; or
(ii) the net IRC § 482 adjustment for the taxable year exceeds the lesser of $20 million or 20% of the taxpayer's gross receipts.
Application to PPC. The per-transaction gross valuation misstatement test (400%/25%) is unlikely to be triggered with respect to any of PPC's intercompany transactions, as the IRS would need to assert that the correct royalty rate is 18.0% or higher (such that PPC's 4.5% is 25% or less of the correct rate), or that the correct rate is 1.125% or lower (such that PPC's 4.5% is 400% or more of the correct rate). Neither scenario appears plausible.
The net adjustment gross valuation misstatement test is more concerning. The $20 million threshold may be triggered if the IRS's total proposed adjustment across all intercompany transactions is sufficiently large. Given the magnitude of PPC's intercompany flows, a total adjustment in the range of $300 million to $400 million (as we anticipate) would produce a tax underpayment at the 21% rate of $63 million to $84 million for TY 2018–2020, and at the 35% rate of potentially even larger amounts for TY 2017, well in excess of the $20 million net adjustment threshold. The 20% of gross receipts threshold (approximately $1.364 billion for FY 2020) is unlikely to be met.
Critically, the reasonable cause/good faith defense and the contemporaneous documentation defense remain available to defeat even the gross valuation misstatement penalty. However, an important distinction applies: under § 6662(h)(3), if the 40% rate applies, the contemporaneous documentation defense alone is insufficient — the taxpayer must independently establish reasonable cause and good faith to avoid the enhanced penalty. This distinction highlights the importance of building a robust reasonable cause defense that is not exclusively dependent on the existence of contemporaneous documentation.
D. IRC § 6662(e)(3)(B) — Exclusion for Taxpayers with Contemporaneous Documentation
IRC § 6662(e)(3)(B) establishes the primary defense mechanism in transfer pricing penalty cases. The provision creates a two-tier protection against the imposition of penalties:
First Tier — General Reasonable Cause. Under § 6662(e)(3)(B)(i), the § 6662(e) penalty shall not apply to any portion of an underpayment if the taxpayer establishes that there was reasonable cause for such portion and that the taxpayer acted in good faith with respect to such portion. This is a general reasonable cause defense, applicable regardless of whether the taxpayer has contemporaneous documentation.
Second Tier — Contemporaneous Documentation Safe Harbor. Under § 6662(e)(3)(B)(ii), a taxpayer that meets the documentation requirements prescribed by the Secretary (i.e., the requirements set forth in Treas. Reg. § 1.6662-6(d)) shall be treated as having established reasonable cause under subparagraph (B)(i) if:
(a) the documentation was in existence at the time the return was filed (i.e., the documentation was "contemporaneous"), and
(b) the taxpayer provides such documentation to the Secretary within 30 days of a request therefor (or such longer period as may be agreed upon between the taxpayer and the Secretary).
The contemporaneous documentation safe harbor effectively creates a rebuttable presumption of reasonable cause: if the taxpayer's documentation meets the regulatory requirements, was in existence at the time of filing, and was timely produced, the taxpayer is treated as having satisfied the reasonable cause standard. This is a powerful defense, as it shifts the focus from the ultimate correctness of the taxpayer's pricing to whether the taxpayer made a genuine, documented effort to comply with the arm's-length standard.
However, the safe harbor is not absolute. The IRS may overcome the presumption of reasonable cause if it demonstrates that the documentation, although formally compliant, is substantively deficient — for example, if the comparables analysis is unreliable, the method selection is unreasonable, or the documentation fails to reflect the actual facts and circumstances of the controlled transactions. This is why the quality and substance of PPC's documentation, not merely its existence, is critical to the penalty defense.
E. Treas. Reg. § 1.6662-6 — Detailed Penalty Regulations for Transfer Pricing
The Treasury Regulations at § 1.6662-6 provide detailed guidance on the application of the transfer pricing penalty provisions and the requirements for contemporaneous documentation.
Documentation Requirements — Treas. Reg. § 1.6662-6(d)(2). The regulations prescribe two categories of documents that a taxpayer must maintain to satisfy the contemporaneous documentation requirements:
Principal Documents. Under Treas. Reg. § 1.6662-6(d)(2)(iii)(B), the principal documents must include:
(i) An overview of the taxpayer's business, including an analysis of the economic and legal factors that affect the pricing of its property or services;
(ii) A description of the taxpayer's organizational structure (including an organization chart) covering all related parties engaged in transactions potentially relevant under IRC § 482;
(iii) Any documentation explicitly required by the regulations under IRC § 482;
(iv) A description of the method selected and an explanation of why that method was selected, including an evaluation of whether the regulatory conditions for the application of that method are met (the "best method" analysis);
(v) A description of the alternative methods that were considered and an explanation of why they were not selected;
(vi) A description of the controlled transactions (including the terms of sale) and any internal data used to analyze those transactions;
(vii) A description of the comparables that were used, how comparability was evaluated, and what adjustments (if any) were made to the comparables;
(viii) An explanation of the economic analysis and projections relied upon in developing the method;
(ix) A description or summary of any relevant data that the taxpayer obtains after the end of the tax year and before filing a tax return, which would help determine if a taxpayer selected and applied a specified method in a reasonable manner; and
(x) A general index of the principal and background documents and a description of the recordkeeping system used for cataloging and accessing those documents.
Background Documents. Under Treas. Reg. § 1.6662-6(d)(2)(iii)(C), background documents include all documents, notes, work papers, records, or other materials that support the assumptions, conclusions, and positions contained in the principal documents. These documents need not be in existence at the time the return is filed but must be maintained and produced upon request.
Contemporaneousness Requirement — Treas. Reg. § 1.6662-6(d)(2)(ii). The principal documents must be in existence when the return is filed. For PPC, which has a December 31 fiscal year-end and files on extension, this means the documentation must be completed and finalized on or before the extended filing deadline (typically October 15 of the following year for corporate returns, or, for years in which further extensions apply, the date the return is actually filed, whichever is earlier). Documentation created after the return is filed is not "contemporaneous" and does not qualify for the safe harbor, although it may still be relevant to the general reasonable cause defense.
Year-Specific Requirements — Treas. Reg. § 1.6662-6(d)(2)(iii)(A). The regulations require that documentation cover each tax year individually. A taxpayer cannot rely on a single multi-year study without year-specific updates to the economic analysis, comparable data, and financial information. While structural elements of the documentation (e.g., business overview, organizational description) need not be entirely rewritten each year, the economic analysis, comparables data, and supporting calculations must be updated annually to reflect the facts and circumstances of the specific tax year. This requirement is particularly important for PPC, as any failure to update the documentation on a year-by-year basis could undermine the contemporaneous documentation defense.
Timely Production Requirement — Treas. Reg. § 1.6662-6(d)(2)(ii). The taxpayer must provide the documentation to the IRS within 30 days of a request, or such later time as may be agreed upon between the taxpayer and the IRS. Failure to produce documentation within the required time frame is treated as a failure to maintain contemporaneous documentation, regardless of whether the documentation actually existed at the time of filing. This underscores the importance of prompt compliance with IDR requests for transfer pricing documentation.
III. Analysis of PPC's Contemporaneous Transfer Pricing Documentation
A. Documentation Prepared by Crestfield & Associates LLP
For each of TY 2017, 2018, 2019, and 2020, Crestfield & Associates LLP prepared contemporaneous transfer pricing documentation under IRC § 6662(e) penalty-protection standards. The documentation engagement was led by Martin Ogilvy (Engagement Partner) and Susan Lam (Transfer Pricing Partner), both of whom are recognized practitioners in the pharmaceutical and life sciences transfer pricing space. Crestfield has served as PPC's transfer pricing documentation provider since at least 2012, and was also responsible for the original PCT valuation analysis and the initial documentation of the CSA at its inception.
The documentation was prepared annually and, based on our review to date, appears to have been in existence prior to the filing of PPC's Forms 1120 for each respective tax year. PPC has a fiscal year-end of December 31 and has consistently filed its federal income tax returns on extension. The extended filing deadlines for the relevant years were as follows: October 15, 2018 (TY 2017); October 15, 2019 (TY 2018); October 15, 2020 (TY 2019); and October 15, 2021 (TY 2020). The documentation packages include date stamps and engagement letter references that are consistent with completion prior to these deadlines, although this point should be confirmed with Crestfield, as discussed in Section IX.A below.
The Crestfield documentation covers both of the principal intercompany transactions at issue:
(a) The qualified cost-sharing arrangement between PPC and PBI, analyzed under Treas. Reg. § 1.482-7, including the determination of PBI's cost-sharing percentages and the allocation of qualified R&D costs; and
(b) The legacy IP royalty arrangement under which PBI pays PPC a royalty of 4.5% of non-Americas net sales for the license of pre-CSA intangible property, analyzed under Treas. Reg. § 1.482-4.
Additionally, the documentation addresses the contract manufacturing arrangement between PBI and Penterra Manufacturing Ireland Ltd. ("PMI"), under which PMI provides contract manufacturing services to PBI at a cost-plus 8% markup, analyzed under the comparable profits method ("CPM") / transactional net margin method ("TNMM").
B. Assessment of Documentation Completeness Against Regulatory Checklist
We have conducted a preliminary review of the Crestfield documentation for all four tax years against the regulatory checklist prescribed by Treas. Reg. § 1.6662-6(d)(2)(iii)(B). Our assessment is as follows:
Business Overview. The Crestfield documentation includes a comprehensive description of PPC's business operations as a specialty pharmaceutical and biotechnology company operating in oncology, immunology, and rare-disease therapeutics. The overview addresses PPC's position in the global pharmaceutical market, its principal product lines, key therapeutic areas, and competitive landscape. The documentation reflects PPC's FY 2020 consolidated revenue of approximately $6.82 billion and its workforce of approximately 14,500 employees globally. The business overview appears to have been updated annually to reflect material changes in PPC's product portfolio, regulatory approvals, clinical pipeline, and financial performance.
Organizational Structure. The documentation describes PPC's relevant corporate structure, including the key entities in the intercompany transaction chain:
• Penterra Pharmaceuticals Corp. (U.S. parent, publicly traded on NYSE: PPHR)
• Penterra Holdings Luxembourg S.à r.l. ("PHL") — a Luxembourg société à responsabilité limitée that is disregarded as separate from PPC for U.S. federal income tax purposes
• Penterra Biopharma International DAC ("PBI") — an Irish designated activity company that serves as the principal IP-holding and licensing entity outside the Americas
• Penterra Manufacturing Ireland Ltd. ("PMI") — an Irish limited company that provides contract manufacturing services to PBI
The organizational charts included in the documentation depict the ownership chain (PPC → PHL → PBI → PMI) and identify the relevant intercompany agreements governing transactions between these entities.
Controlled Transactions Documented. The documentation addresses the following controlled transactions in detail:
CSA Cost-Sharing. PBI's cost-sharing percentages were determined based on reasonably anticipated benefit ("RAB") projections, with PBI's share increasing from 38.2% in TY 2017 to 42.7% in TY 2020, reflecting PBI's growing share of projected revenues from covered intangibles in non-Americas markets. The annual qualified R&D costs to which these percentages were applied were $487.3 million (TY 2017), $523.8 million (TY 2018), $561.2 million (TY 2019), and $598.4 million (TY 2020). The documentation includes the RAB projections, revenue forecasts by geographic segment, and the resulting cost-sharing calculations for each year.
Legacy IP Royalty. The documentation supports the 4.5% royalty rate applied to PBI's non-Americas net sales for the license of pre-CSA intangible property. Non-Americas net sales subject to the royalty declined from $814.6 million in TY 2017 to $624.1 million in TY 2020, reflecting the natural erosion of legacy product sales and the growing contribution of post-CSA intangibles to PBI's revenue base. The documentation includes the CUT (comparable uncontrolled transaction) analysis supporting the 4.5% rate.
PMI Contract Manufacturing. The documentation supports the cost-plus 8% markup applied to contract manufacturing services provided by PMI to PBI. This transaction is not currently a primary focus of the IRS examination but is documented as part of the comprehensive transfer pricing analysis.
PCT. The original PCT payment of $312 million, made by PBI to PPC on July 1, 2012, is referenced in the documentation for each year as historical background for the CSA. The original PCT valuation, based on a discounted cash flow ("DCF") analysis, is included in the background documents. The ongoing cost-sharing and royalty methodologies are independently documented for each year and do not depend solely on the PCT valuation.
Method Selection and Best Method Analysis. The documentation applies the following methods:
• CUT Method for the legacy IP royalty rate, based on comparable uncontrolled license agreements in the pharmaceutical and biotechnology sectors;
• CPM/TNMM for evaluating PBI's operating margins from exploitation of licensed and cost-shared intangibles, as well as for the PMI contract manufacturing arrangement; and
• Income Method (DCF) for the PCT valuation, consistent with Treas. Reg. § 1.482-7(g)(4).
For each method, the documentation includes a discussion of why the selected method was chosen as the "best method" under Treas. Reg. § 1.482-1(d), including an assessment of the degree of comparability between the controlled and uncontrolled transactions, the quality of the available data, and the reliability of the assumptions underlying the analysis. The documentation also discusses alternative methods that were considered and the reasons they were not selected, consistent with the regulatory requirement.
Comparables Search and Analysis. The documentation includes comparables searches and economic analyses supporting the arm's-length nature of PPC's intercompany pricing. For the CUT analysis of the royalty rate, the documentation identifies comparable uncontrolled license agreements sourced from publicly available databases and proprietary Crestfield datasets. For the CPM/TNMM analysis, the documentation includes searches for comparable companies using standard financial databases.
However, the depth and currency of the comparable data will need to be assessed against the standards applied by courts in transfer pricing penalty cases. As discussed in Section V below, courts have scrutinized the rigor of comparables searches, the relevance and reliability of selected comparables, and the adequacy of comparability adjustments. We recommend that C&H coordinate with Whitmore Valuation Group to assess whether the Crestfield comparables searches and analyses would withstand IRS and judicial scrutiny, and whether supplemental analysis may be advisable to bolster the reasonableness of PPC's positions.
Economic Analysis. Each year's documentation includes quantitative analysis supporting the arm's-length nature of the intercompany pricing. The analysis includes computation of PBI's operating margins, comparison to arm's-length ranges derived from comparable company data, reconciliation of cost-sharing ratios to RAB projections, and sensitivity analyses testing the impact of key assumptions on the reported results. The economic analysis is supported by detailed work papers and financial data for PPC and PBI.
C. Timeliness of Production
IDR No. 4, issued by the IRS examination team approximately in August 2022, requested the contemporaneous transfer pricing documentation for all four tax years (TY 2017–2020). C&H, on behalf of PPC, responded on August 1, 2022, producing the complete Crestfield-prepared documentation packages for all four years. This production was made well within the 30-day production window prescribed by Treas. Reg. § 1.6662-6(d)(2)(ii).
No timeliness objection is available to the IRS with respect to PPC's production of contemporaneous documentation. The documentation was produced promptly, in an organized format, with an index of principal and background documents. The production was accompanied by a cover letter identifying the documents produced and reserving applicable privilege claims with respect to documents withheld under the attorney-client privilege and work product doctrine, consistent with the privilege protocol established by Leonard Cross in a separate memorandum dated June 10, 2022.
D. Potential Weaknesses in Documentation
Notwithstanding the overall strength of PPC's documentation, our preliminary review has identified several areas that require further investigation and, potentially, remediation:
Year-Specific Updating. We need to verify that each year's documentation was independently updated with year-specific financial data, comparables analysis, and economic analysis, and that the documentation does not consist merely of boilerplate carryforwards from prior years with only cosmetic modifications. The regulations require year-specific documentation, and courts have penalized taxpayers whose documentation was essentially a "cut and paste" of prior-year studies without meaningful updates. Specifically, we should confirm that the RAB projections, revenue forecasts, comparable data sets, and financial metrics used in the economic analysis were independently developed or updated for each tax year.
Completeness of Transaction Coverage. We need to confirm that the documentation addresses all transactions the IRS is examining, including whether the CSA cost-sharing ratio calculations are supported with sufficient detail on the RAB projections — specifically, the methodology for projecting PBI's share of reasonably anticipated benefits from covered intangibles, the revenue forecasting models used, and the treatment of pipeline products at various stages of clinical development. If the documentation fails to address any material aspect of the transactions under examination, this gap could be exploited by the IRS in asserting that the documentation is incomplete and therefore does not satisfy the regulatory requirements.
PCT Valuation Linkage. The original PCT valuation of $312 million was performed in 2012, outside the examination years. The documentation for TY 2017–2020 appropriately references the PCT as historical background, but the critical question is whether the ongoing CSA and royalty methodologies are independently documented each year without excessive reliance on the 2012 PCT analysis. If the IRS challenges the PCT valuation and argues that the downstream cost-sharing and royalty arrangements are infected by the same purported errors, PPC's penalty defense will need to demonstrate that the current-year documentation independently supports the arm's-length nature of the ongoing transactions, regardless of the PCT valuation.
Documentation Preparation Timeline. We should obtain from Crestfield (Susan Lam) a detailed description of the documentation preparation process and timeline for each year, including when the engagement was initiated, when draft and final documentation packages were completed, and how the completion dates relate to PPC's return filing dates. This information will be critical in confirming the contemporaneousness of the documentation and in responding to any IRS challenge on this point.
Recommendation. C&H should schedule a meeting with Susan Lam and the Crestfield team at the earliest opportunity to (i) obtain confirmation of the documentation preparation process and timeline for each year, (ii) identify any gaps in year-specific updating, (iii) assess the robustness of the comparables searches and economic analyses, and (iv) discuss any limitations or caveats noted by Crestfield in their engagement letter or documentation deliverables. The results of this meeting should be documented in a follow-up memorandum to the file.
IV. Reasonable Cause and Good Faith Defense — General Standards
Even if the IRS were to contend that PPC's contemporaneous documentation does not fully satisfy the regulatory checklist, PPC retains the general reasonable cause and good faith defense under IRC § 6664(c). This defense is available independently of the contemporaneous documentation safe harbor and may provide an additional layer of protection against the imposition of penalties.
A. Statutory Framework — IRC § 6664(c)
IRC § 6664(c)(1) provides that no penalty shall be imposed under § 6662 with respect to any portion of an underpayment if it is shown that there was reasonable cause for such portion and that the taxpayer acted in good faith with respect to such portion. The statute contemplates a two-part inquiry: (1) whether the taxpayer had "reasonable cause" for the position giving rise to the underpayment, and (2) whether the taxpayer "acted in good faith" in reporting the position on the return.
The burden of proof rests on the taxpayer. PPC must affirmatively demonstrate, by a preponderance of the evidence, that its transfer pricing positions were adopted for reasonable cause and in good faith. This determination is made on a case-by-case basis, taking into account all pertinent facts and circumstances. There is no mechanical test for reasonable cause; rather, the inquiry is inherently fact-intensive and turns on the totality of the circumstances surrounding the taxpayer's reporting position.
B. Treas. Reg. § 1.6664-4 — Reasonable Cause and Good Faith
The Treasury Regulations at § 1.6664-4 provide detailed guidance on the factors relevant to the reasonable cause and good faith determination. The regulations identify several factors that are generally accorded significant weight:
(i) Efforts to Assess Proper Tax Liability. The regulations look to the nature of the taxpayer's efforts to assess its proper tax liability. A taxpayer that takes affirmative steps to determine the correct tax treatment of a transaction — such as engaging qualified professionals, conducting economic analyses, and preparing detailed documentation — is more likely to establish reasonable cause than a taxpayer that takes a reporting position without any supporting analysis.
(ii) Experience, Knowledge, and Education. The taxpayer's own expertise and sophistication are relevant factors. However, the regulations do not penalize sophistication; rather, a sophisticated taxpayer is expected to recognize the complexity of its transactions and to take correspondingly greater care in determining the correct treatment. The regulations acknowledge that even sophisticated taxpayers may reasonably rely on the judgment of qualified professionals in areas of specialized expertise, such as transfer pricing economics.
(iii) Reliance on Professional Advice. A taxpayer's reliance on professional advice is among the most important factors in the reasonable cause analysis. Reliance on professional advice constitutes reasonable cause if three conditions are met:
(a) The adviser was a competent professional who had sufficient expertise to justify reliance — in the transfer pricing context, this typically means an economist or transfer pricing specialist with relevant industry experience;
(b) The taxpayer provided necessary and accurate information to the adviser — i.e., the taxpayer did not withhold material facts or provide misleading data; and
(c) The taxpayer actually relied in good faith on the adviser's judgment — i.e., the reliance was genuine and not merely a post hoc rationalization.
The sophistication of the taxpayer is a relevant factor in assessing the reasonableness of reliance on professional advice. However, even sophisticated taxpayers — including large, publicly traded companies like PPC — can establish reasonable cause through reliance on qualified advisors, particularly in the highly specialized and technical area of transfer pricing economics. The key question is whether the taxpayer's reliance was genuine and reasonable under the circumstances, not whether the taxpayer could theoretically have reached its own conclusion without professional assistance.
C. Application to Transfer Pricing Specifically — Treas. Reg. § 1.6662-6(d)
Under the transfer pricing penalty regulations at Treas. Reg. § 1.6662-6(d), the existence of qualifying contemporaneous documentation creates a rebuttable presumption of reasonable cause. This presumption is the foundation of the contemporaneous documentation safe harbor discussed in Section II.D above.
Importantly, even if the documentation does not fully meet the regulatory checklist — for example, if there are arguable gaps in the comparables analysis, or if certain elements of the best method discussion are less detailed than optimal — a taxpayer may still establish reasonable cause and good faith through other evidence. The regulations contemplate that the quality and detail of the documentation is a factor in the reasonable cause analysis, not a bright-line test. A taxpayer whose documentation substantially (but not perfectly) satisfies the regulatory requirements, and who can demonstrate reliance on qualified professionals and a genuine effort to comply with the arm's-length standard, may nonetheless avoid penalties.
Courts have consistently emphasized that the reasonable cause inquiry in transfer pricing cases focuses on whether the taxpayer made a genuine, good-faith effort to comply with the arm's-length standard — not on whether the taxpayer's position ultimately prevails on the merits. The fact that the IRS disagrees with the taxpayer's transfer pricing methodology or reaches a different arm's-length result does not, standing alone, establish that the taxpayer lacked reasonable cause. To the contrary, the existence of legitimate methodological disputes — which are common in the transfer pricing area given the inherent subjectivity of arm's-length pricing determinations — tends to support, rather than undermine, the taxpayer's reasonable cause defense.
V. Case Law on Transfer Pricing Penalties and Reasonable Cause
The case law on transfer pricing penalties under IRC § 6662(e) provides important guidance on the standards courts apply in evaluating the contemporaneous documentation defense and the reasonable cause defense. While each case turns on its own facts, several principles emerge from the decided cases that are instructive for PPC's penalty defense.
A. Cases Upholding Penalty Protection
A number of cases have found taxpayers entitled to penalty protection based on adequate contemporaneous documentation and/or reasonable cause. These cases illustrate the types of taxpayer conduct that courts view favorably in the penalty context.
Reliance on Qualified Economists and Robust Benchmarking Studies. Courts have consistently held that a taxpayer's engagement of qualified economists to prepare transfer pricing documentation and benchmarking studies weighs strongly in favor of reasonable cause. Where the taxpayer retained professionals with recognized expertise in transfer pricing economics, provided them with accurate and complete information, and relied on their professional judgment in setting intercompany prices, courts have found that the taxpayer acted in good faith. This principle is directly analogous to PPC's engagement of Crestfield & Associates for original documentation and Whitmore Valuation Group for independent economic analyses in connection with the examination.
Good-Faith Reliance on Professional Advisors. Courts have recognized that reliance on the advice of qualified tax professionals — including transfer pricing economists, tax attorneys, and valuation specialists — is a strong indicator of reasonable cause. The reliance need not be blindly mechanical; rather, the taxpayer must demonstrate that it provided its advisors with relevant information, that the advisors applied recognized methodologies to the facts, and that the taxpayer adopted the resulting pricing in good faith. In PPC's case, the engagement of Crestfield for transfer pricing documentation, the retention of C&H for examination defense, and the engagement of Whitmore Valuation Group under a Kovel arrangement all demonstrate a pattern of professional reliance that courts have found persuasive.
Defensible Range Supported by Economic Analysis. Courts have also been reluctant to impose penalties where the taxpayer's transfer pricing position, even if not ultimately sustained, falls within a defensible range supported by economic analysis. A taxpayer whose pricing is within the interquartile range (or even reasonably close to it) of a reliable comparables study is generally not viewed as having engaged in conduct warranting penalties. The fact that the IRS may identify a different arm's-length result, or that the court may adopt a different point within the arm's-length range, does not establish that the taxpayer's position was unreasonable. This principle is particularly relevant to PPC's legacy royalty rate of 4.5%, which falls virtually at the median (4.4%) of the interquartile range (3.1%–6.8%) identified by Whitmore Valuation Group's CUT analysis.
B. Cases Where Penalties Were Sustained
Courts have sustained transfer pricing penalties in cases presenting markedly different facts from those present here. An examination of these cases helps identify the types of conduct that courts view as warranting penalties and, by contrast, the distinctions that support PPC's penalty defense.
Absence of Contemporaneous Documentation. The most straightforward basis for sustaining penalties is the complete absence of any contemporaneous documentation. Where taxpayers failed to prepare any transfer pricing documentation — or prepared documentation only after the IRS opened an examination — courts have consistently found the taxpayer ineligible for the contemporaneous documentation safe harbor and have analyzed the general reasonable cause defense with heightened skepticism. PPC's situation is fundamentally distinguishable: Crestfield prepared contemporaneous documentation for all four tax years, and PPC timely produced the documentation within 30 days of the IRS's request.
Formulaic or Boilerplate Documentation. Courts have also imposed penalties where the taxpayer's documentation was merely formulaic or boilerplate — i.e., identical language repeated across multiple years without year-specific analysis, financial data, or updated comparables. Such documentation fails to demonstrate a genuine effort to comply with the arm's-length standard and does not satisfy the year-specific requirement of Treas. Reg. § 1.6662-6(d)(2)(iii)(A). This risk factor underscores the importance of confirming, as recommended in Section III.D above, that PPC's Crestfield documentation was independently updated for each tax year.
Inadequate Comparables Searches. Courts have scrutinized the rigor of taxpayers' comparables searches and have imposed penalties where the search process was demonstrably inadequate — for example, where the taxpayer selected only favorable comparables while ignoring more reliable comparables that would have produced a different result, or where the search was conducted using overly narrow criteria designed to produce a predetermined outcome. For PPC, the quality of the comparables searches conducted by Crestfield will be a focus of the IRS's penalty analysis, and any weaknesses in the search methodology could be exploited by the IRS.
Unreasonable Method Selection. Penalties have been sustained where the taxpayer's selected method lacked a reasonable basis under the best method rule of Treas. Reg. § 1.482-1(d) — for example, where the taxpayer applied a method that was plainly inferior to an available alternative, or where the taxpayer failed to make appropriate comparability adjustments. PPC's method selections (CUT for royalties, CPM/TNMM for operating margins, income method for PCT) are well-established and widely used in pharmaceutical transfer pricing; the risk on this factor is relatively low, provided the documentation adequately explains the rationale for each method selection.
Untimely Production. Courts have treated untimely production of documentation as equivalent to non-production for purposes of the contemporaneous documentation defense. As noted in Section III.C above, PPC's timely production within 30 days of the IRS's request eliminates this risk.
Key Takeaways for PPC. PPC must be prepared to demonstrate that its documentation is not pro forma but reflects genuine economic analysis tailored to each tax year. The documentation should be presentable as a package that demonstrates, on its face, a serious, good-faith effort to determine arm's-length pricing — not merely a compliance exercise designed to check regulatory boxes. To the extent any weaknesses exist in the Crestfield documentation, they should be identified promptly and addressed through supplemental analyses and testimony.
C. Relevance of Altera and Harborview Corporation Line of Cases
Two recent lines of appellate and Tax Court authority are particularly relevant to PPC's penalty analysis, given their involvement of pharmaceutical intangibles and CSA structures.
Altera Corp. v. Commissioner. In Altera Corp. v. Commissioner, 941 F.3d 1200 (9th Cir. 2019), the Ninth Circuit addressed whether Treas. Reg. § 1.482-7(d)(2) — which required participants in qualified cost-sharing arrangements to share stock-based compensation costs — was a valid exercise of the Treasury Department's regulatory authority. The court upheld the regulation, reversing the Tax Court's decision to the contrary. Although the penalty issues in Altera were not the central focus of the appellate decision, the case is relevant to the extent it establishes the validity of the cost-sharing regulations that PPC's CSA is structured to comply with. Importantly, Altera does not establish that a taxpayer's good-faith reliance on a reasonable interpretation of the cost-sharing regulations — even one that is ultimately rejected by the courts — automatically gives rise to penalties. The key question remains whether the taxpayer's position was adopted in good faith based on reasonable professional advice.
Harborview Corporation, Inc. v. Commissioner. The Harborview Corporation litigation, which involved transfer pricing for medical device intangibles licensed to a Puerto Rico manufacturing subsidiary, is closely analogous to PPC's situation. In Harborview Corporation, Inc. v. Commissioner, 900 F.3d 610 (8th Cir. 2018), the Eighth Circuit remanded the case to the Tax Court for reconsideration of the transfer pricing methodology after finding that the Tax Court had erred in its application of the CUT method. On remand, in Harborview Corporation, Inc. v. Commissioner, T.C. Memo. 2022-84, the Tax Court again addressed the appropriate transfer pricing methodology and, relevantly, the penalty issues arising from the IRS's proposed adjustments to royalty payments for pharmaceutical and medical device intangibles.
The penalty implications of Harborview Corporation are significant for PPC: the case illustrates that the IRS's disagreement with a taxpayer's CUT methodology — even where the court ultimately rejects the taxpayer's specific comparable and adopts a different approach — does not automatically warrant penalties. The existence of a legitimate methodological dispute, supported by economic analysis, is not the type of conduct the penalty provisions are designed to address. To the contrary, the penalty provisions target situations where the taxpayer failed to make a good-faith effort to comply with the arm's-length standard — not situations where qualified professionals applied recognized methodologies and reached a defensible (if ultimately incorrect) conclusion.
Neither Altera nor Harborview Corporation established that having a legitimate methodological dispute with the IRS, supported by economic analysis, automatically triggers penalties. Rather, the weight of authority supports the proposition that where the taxpayer's position is supported by a reasonable economic methodology, applied in good faith by qualified professionals, penalties are generally not sustained.
VI. Application to PPC's Specific Positions
This Section applies the statutory, regulatory, and case law framework discussed above to each of PPC's specific transfer pricing positions at issue in the examination.
A. CSA Cost-Sharing Ratios
PPC's cost-sharing ratios, under which PBI bore 38.2% (TY 2017), 39.6% (TY 2018), 41.1% (TY 2019), and 42.7% (TY 2020) of annual qualified R&D costs, are based on reasonably anticipated benefit ("RAB") projections derived from revenue forecasts for Americas versus non-Americas territories. The cost-sharing methodology is grounded in Treas. Reg. § 1.482-7(e), which prescribes the use of RAB shares as the basis for allocating intangible development costs among CSA participants.
The Crestfield documentation details the projection methodology and supporting data used to derive PBI's cost-sharing percentages, including revenue forecasts by product and geographic segment, the treatment of pipeline products at various stages of clinical development, and the expected trajectory of product launches and market penetration in non-Americas territories. PBI's increasing share over the four-year period (from 38.2% to 42.7%) reflects the growing contribution of non-Americas markets to PPC's global revenue mix, driven by PBI's expanding commercial operations and portfolio of marketed products.
If the IRS proposes an increase of 8 to 12 percentage points in PBI's cost-sharing ratios — for example, asserting that PBI's share should have been approximately 46% to 55% — the critical question for penalty purposes is whether PPC's original ratios are so far from the correct ratios as to constitute a substantial valuation misstatement. We believe the penalty defense is strong for several reasons:
First, PPC's cost-sharing methodology is grounded in the regulations and is based on a recognized approach to projecting RAB shares. The use of revenue-based projections, adjusted for geographic market characteristics and product lifecycle factors, is a standard methodology employed by large pharmaceutical companies in structuring and documenting CSAs.
Second, the methodology was documented in detail by qualified professionals (Crestfield & Associates) on a contemporaneous, annual basis, with year-specific financial data and updated revenue projections for each tax year.
Third, the nature of the disagreement between PPC and the IRS is likely to involve subjective assumptions about future revenues, discount rates, and market growth — exactly the type of legitimate methodological dispute that courts have recognized as a basis for penalty protection, not penalty imposition.
The $5 million net adjustment threshold under § 6662(e)(1)(B)(ii) will likely be exceeded on the CSA component alone, as even a modest percentage increase in PBI's cost-sharing ratios, applied to annual qualified R&D costs of $487 million to $598 million, could produce additional U.S. taxable income in excess of $5 million per year. However, exceeding this threshold merely triggers the penalty inquiry — it does not foreclose the reasonable cause defense. As discussed in Section IV above, PPC can establish reasonable cause through contemporaneous documentation and reliance on qualified professional advisors, regardless of the magnitude of the adjustment.
B. Legacy IP Royalty Rate (4.5%)
PPC's legacy IP royalty rate of 4.5% of non-Americas net sales is based on a CUT analysis conducted by Crestfield as part of the contemporaneous documentation for each year, and independently validated by Whitmore Valuation Group in connection with the current examination.
Whitmore's CUT analysis, conducted by Dr. Helena Vasquez and Dr. Rohan Chakrabarti, identified 14 comparable uncontrolled pharmaceutical license agreements involving the out-licensing of oncology, immunology, and specialty pharmaceutical intangibles to unrelated licensees. The agreements were sourced from publicly available databases (including Vireo Health IT, Sundial Health IT, and the SEC EDGAR filing database) and from Whitmore's proprietary transaction database. After applying comparability adjustments for differences in therapeutic area, stage of development, geographic scope, exclusivity provisions, and remaining patent life, the analysis produced an interquartile range of 3.1% to 6.8% with a median of 4.4%.
PPC's royalty rate of 4.5% is virtually at the median of the comparable range (4.4%) and well within the interquartile range (3.1%–6.8%). This positioning provides strong penalty protection:
Under the standards discussed in Section V above, courts have consistently held that a taxpayer whose transfer pricing falls within the interquartile range of a reliable comparables study has demonstrated reasonable cause for its pricing. The fact that the IRS may propose a higher rate does not establish that PPC's rate was unreasonable — it merely reflects a difference of professional judgment in the application of the CUT method.
Even if the IRS were to propose an arm's-length rate of 11.0% — a position that, if sustained, would imply that PPC's 4.5% rate is approximately 40.9% of the correct rate and would trigger the per-item 50% test under § 6662(e)(1)(B)(i) — PPC's penalty defense would remain strong. The per-item test merely triggers the penalty inquiry; it does not override the reasonable cause defense. PPC's reliance on a CUT analysis supported by 14 pharmaceutical comparables, conducted by qualified professionals using recognized databases and methodologies, constitutes strong reasonable cause for the 4.5% rate regardless of whether the IRS proposes a significantly different rate.
Moreover, the 200%/50% test analysis depends on the IRS's ultimate adjustment being sustained, which is the very question in dispute. If the IRS proposes an 11.0% rate but the ultimate arm's-length rate (as determined through settlement or litigation) is less than 9.0%, the per-item test would not be triggered at all. The penalty analysis thus cannot be divorced from the substantive merits of PPC's transfer pricing position, which we believe are defensible.
C. PCT Valuation ($312M)
While the PCT payment of $312 million was made on July 1, 2012, outside the examination years (TY 2017–2020), the IRS may attempt to use the PCT valuation as a basis for adjusting ongoing cost-sharing and royalty arrangements during the examination period. Specifically, the IRS may argue that the PCT undervalued the pre-existing intangible property contributed by PPC to the CSA, and that this undervaluation has cascading effects on the cost-sharing ratios and royalty rates applied in subsequent years.
PPC's PCT valuation is supported by a DCF analysis prepared by Crestfield at the time of the CSA inception in 2012. The analysis applied a weighted average cost of capital ("WACC") of 9.8%, reflecting PPC's blended cost of debt and equity at the time of the transaction, adjusted for the risk characteristics of the intangible property portfolio being contributed. Whitmore Valuation Group has independently reviewed the PCT valuation and, applying a range of discount rates reflecting comparable pharmaceutical company WACCs and asset-specific risk premiums, has concluded that the arm's-length range for the PCT payment is $278 million to $361 million. PPC's actual payment of $312 million falls comfortably within this range.
The IRS is expected to take the position that the appropriate WACC is lower — potentially 7.2%, reflecting a more favorable risk assessment of the contributed intangibles — which would increase the present value of the intangible property and, consequently, the implied arm's-length PCT payment. However, the difference between a 9.8% WACC and a 7.2% WACC represents a legitimate professional disagreement on the appropriate risk-adjusted discount rate for pharmaceutical intangibles, not the type of egregious or unreasonable position that warrants penalties.
The use of a defensible WACC, based on recognized valuation methodologies and supported by comparable company data, constitutes strong reasonable cause for the PCT valuation and for any downstream adjustments flowing from the PCT to the ongoing cost-sharing and royalty arrangements. Moreover, the ongoing CSA cost-sharing ratios and royalty rates are independently documented and supported by separate economic analyses for each tax year, so the penalty defense does not rest solely on the PCT valuation.
D. PBI Economic Substance
The IRS may challenge the economic substance of PBI as part of its broader attack on PPC's transfer pricing structure. While economic substance is more directly relevant to the underlying adjustment (i.e., whether PBI should be respected as a separate entity for transfer pricing purposes) than to the penalty analysis per se, PBI's substance is nonetheless relevant to the penalty defense in two respects.
First, to the extent the IRS argues that PBI is a sham entity without genuine business operations, PPC's documentation of PBI's substance demonstrates that PPC had a good-faith basis for treating PBI as a genuine operating entity with sufficient substance to justify its role as IP owner and CSA participant. PPC can point to the following indicators of PBI's economic substance:
• PBI employed 185 personnel as of the end of 2020, up from 52 employees at the time of the CSA inception in 2012, reflecting significant growth in PBI's operational capabilities over the examination period;
• PBI's board of directors held 42 board meetings in Dublin during TY 2017–2020 (an average of more than 10 meetings per year), at which the board exercised independent judgment on pricing decisions, licensing strategy, regulatory matters, and business development;
• PBI incurred cumulative regulatory expenditures of €47.2 million during TY 2017–2020,

PRIVILEGED AND CONFIDENTIAL ATTORNEY WORK PRODUCT

CALDERWOOD & HARKNESS LLP

MATTER NUMBER: 1018-00009

EXAM TEAM ID: LB&I-NE-TP-2022-00641

Record

Parties

Dates

Amounts